Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI and Real-World Clinical Data for Precision Cancer Drug Development
Collaboration to identify optimal combination therapies, predictive biomarkers and patient populations for Rakovina’s ATR inhibitor program VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF) a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced a research…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
